Three AI labs named 23 health launch customers and no FQHCs

The same pattern at all three labs

Anthropic's launch roster: AstraZeneca, Sanofi, Genmab, Banner Health, Stanford Healthcare, Novo Nordisk, AbbVie, Veeva, Flatiron Health. Six pharma companies, two academic medical centers, one health-tech vendor.

Banner Health's deployment is impressive — 22,000+ clinical providers, BannerWise private chatbot, 85% of users report working faster. The 8-hour-per-patient pre-visit chart summarization Banner runs for oncology patients now takes minutes.

The deployment proves Claude works at enterprise scale. The roster doesn't include a single Federally Qualified Health Center.

OpenAI's launch roster: AdventHealth, Baylor Scott & White Health, Boston Children's Hospital, Cedars-Sinai Medical Center, HCA Healthcare, Memorial Sloan Kettering Cancer Center, Stanford Medicine Children's Health, UCSF. Eight large hospital systems and academic medical centers.

Plus a separate consumer product, ChatGPT Health, that connects personal medical records via b.well's 2.2 million-provider partnership. FQHC patients access ChatGPT Health indirectly through b.well — but FQHCs themselves have no enterprise tier deployment.

Google Cloud's launch roster: Humana, CVS Health (Health100), Highmark Health (Sidekick), Waystar (AltitudeAI), Quest Diagnostics, WellSky (20,000+ post-acute / community care sites). Four payers, one diagnostics company, one post-acute network.

Highmark Sidekick grew from 1M to 6M+ prompts in 2025, delivering $27.9M in AI-enabled value. Waystar AltitudeAI prevented $15B+ in denied claims.

The WellSky partnership covers 20,000+ care sites — the closest analog to OCHIN's 2,200+ FQHC site network. The architecture is built for consortium-distributed AI deployment. The FQHC consortium partnership doesn't exist.

Clinical leadership at each lab

Different labs have built clinical bench depth in very different ways. This matters for FQHCs evaluating which lab actually understands clinical workflow.

Google Cloud has the deepest formal clinical leadership: a Chief Health Officer (Michael Howell MD, who succeeded Karen DeSalvo MD MPH MSc in summer 2025) and a PhD-led Health AI division (Greg Corrado PhD, who co-founded Google Brain). Plus the Med-PaLM legacy of peer-reviewed clinical AI papers. This is the most credentialed clinical bench across the three labs.

OpenAI's clinical leadership is anchored on Nate Gross MD — co-founder of Doximity, the largest US physician network, with a practicing-physician background. Plus 'hundreds of physician advisors' informed ChatGPT for Clinicians, which is FREE for individual physicians, NPs, and pharmacists.

That's the differentiator: any FQHC clinician can pilot ChatGPT for Clinicians personally without procurement. No other AI lab offers a free clinician tier.

Anthropic has the thinnest publicly named clinical bench. CEO Dario Amodei holds a PhD in physics; co-founders are technologists and policy professionals. There is no publicly named Chief Medical Officer. Anthropic builds healthcare on top of the general Claude API rather than deploying a healthcare-specific clinical leadership function.

This isn't necessarily disqualifying — Banner Health's 22,000-clinical-provider deployment proves Claude scales — but it is a notable gap relative to OpenAI and Google.

Wardly AI, the early-stage pre-visit intake startup, names two clinical advisors / customers publicly: Dr. Prince Shah MD FACP FACG (founder of Gilroy Gastroenterology, California) and Adam Tilson PA-C (Director of Adult Medicine at Aizer Health). Academic logos displayed include UC Berkeley, Thomas Jefferson University, and Penn State.

For an early-stage company, this is meaningful clinical bench depth — but no MD/NP/PhD is on the founding team.

What the gap means for FQHCs

First, FQHC populations are not represented in the launch-customer alignment work. Foundation model AI trained predominantly on academic medical center data and pharma research data underperforms on safety-net panels — Spanish-first, multi-comorbidity, fragmented prior records from migration patterns, low health literacy.

The same equity question that applies to Epic Cosmos / CoMET training data applies to all three AI lab healthcare products. The launch customers shape what 'works' looks like.

Second, FQHCs absorb the patient-facing externality without partnership benefit. ChatGPT Health connects FQHC patients (via b.well) to AI-mediated health navigation. FQHC providers will increasingly encounter 'I asked ChatGPT and it said...' visits, and Anthropic's HealthEx partnership creates the same dynamic for Claude Pro users.

FQHCs handle the operational consequences — patient confusion, AI hallucinations, expectation management — without an enterprise relationship that would let them shape patient-facing AI behavior.

Third, the partnership architecture exists. WellSky's 20,000+ post-acute site partnership with Google Cloud is functionally equivalent to what OCHIN's 2,200+ site FQHC network could be with any of the three labs. The technology integration model is proven. The bargaining-leverage scale is there. What's missing is the consortium-broker willing to pull the partnership across the line.

Results from named case studies

Anthropic Claude case studies (verified): Banner Health 22,000+ clinical providers, 85% report working faster, 1,400+ oncology notes processed, 8-hour-to-minutes chart summarization. Stanford Health Care built ChatEHR on Claude.

Elation Health reports a 61% drop in documentation time. Carta Healthcare reports 66% reduction in clinical data processing time with 99% accuracy.

OpenAI ChatGPT case studies (verified): launch customers AdventHealth (51 hospitals), HCA Healthcare (188 hospitals — largest of the launch roster), UCSF, Memorial Sloan Kettering. Specific outcome metrics from these enterprise pilots have not yet been publicly disclosed at the depth Anthropic / Google have published.

Google Cloud case studies (verified): Highmark Sidekick — 1M to 6M+ prompts, $27.9M AI-enabled value 2025. Waystar AltitudeAI — $15B+ in denied claims prevented, 90% reduction in appeal/documentation workflows. Humana Agent Assist — Gemini Enterprise CX background support. Merck — $1B+ multi-year agentic AI deal. WellSky — Gemini multimodal models across 20,000+ care sites.

Wardly AI case studies (verified): Gilroy Gastroenterology (Dr. Prince Shah MD founder testimonial — pre-visit AI calls capture symptoms + prior evaluation history before GI visits), Aizer Health (Adam Tilson PA-C testimonial — adult medicine pre-visit intake). Specific metrics not publicly disclosed at the depth larger competitors have published.

What changed after publication

Three updates have shifted the picture since the May 1, 2026 publication date — and they soften the original argument without refuting its core thesis.

First, Anthropic released Claude Opus 4.7 on April 16, 2026 at $5 input / $25 output per million tokens — the same pricing as Opus 4.6, as Anthropic's launch post states explicitly. The $15/$75 figure belongs to Opus 4.1, retired August 5, 2026.

The model carries a 1 million token context window (large enough to hold a multi-year FQHC patient record in a single inference), hybrid reasoning, and a January 2026 knowledge cutoff. It is also available on Amazon Bedrock with HIPAA-eligible deployments.

For FQHCs, the cost/benefit math on Claude for clinical-support, RCM-assist, and care-plan synthesis is materially different than it was at JPMHC 2026. It does not, however, change the launch-customer composition — no FQHC has been named as a Claude Opus 4.7 launch partner.

Second, NACHC IS getting a seat at the AI-governance table. On May 11, 2026, the Coalition for Health AI (CHAI) released Medicaid-eligibility AI best-practice guides co-chaired by Centene, NACHC, HealthTech 4 Medicaid, and Pair Team — the first time NACHC has co-chaired a national AI-governance work product.

The guides are specifically scoped to the eligibility-determination context that affects nearly every CHC patient.

This is meaningful: NACHC is no longer just on the receiving end of foundation-model AI, it's now co-shaping the governance framework. It doesn't refute the original "0 FQHC launch partners with the Big 3 frontier labs" finding — but it does mean NACHC's posture has shifted from absent to engaged.

Third, California AB 3030 and SB 1120 are now active compliance triggers for any CA FQHC deploying any of the labs' tools. AB 3030 requires mandatory patient disclosure plus explicit consent BEFORE AI is used in patient care.

SB 1120 requires that a human clinician make the final medical-necessity call in any utilization-management decision that touches AI.

If your FQHC is in California and pilots Claude for Healthcare, ChatGPT Health, or Gemini-powered clinical tools, both statutes apply — including to the personal Claude Pro / ChatGPT Pro / Gemini Advanced pilots recommended below.

What FQHC leaders can do this quarter

Four concrete moves before your next executive team meeting.

• Audit existing AI usage for AB 3030 compliance. Survey your clinicians: who is already using ChatGPT, Claude, Gemini, or OpenEvidence in patient-facing work? AB 3030 requires a disclaimer on patient communications generated by AI, plus clear instructions for reaching a human — with a safe harbor when a licensed provider reviews the message before it goes out. It does not, on its own, require consent before an AI is engaged; the duty to get consent before recording a conversation comes from CIPA (Penal Code 632). If your clinic doesn't have an AB 3030 disclaimer script, draft one this quarter — your compliance officer should own it, your CMO should approve it, and your intake staff should be trained to deliver it. SB 1120 separately requires a human clinician to make the final medical-necessity call on any UM decision that touches AI.
• Send a partnership inquiry to all three AI labs. Anthropic does not name a Chief Medical Officer publicly — escalate to your Anthropic enterprise account manager or via the Claude for Healthcare contact form. For OpenAI, escalate to Nate Gross's team via the ChatGPT for Healthcare page. For Google Cloud, engage Michael Howell MD's Chief Health Officer team.
• Pilot ChatGPT for Clinicians personally. It's free for verified physicians, NPs, and pharmacists. Have 3-5 of your providers try it for 30 days on documentation, medical research, and clinical task assistance. Compare against Claude Pro ($20/mo) and Gemini Advanced ($20/mo) for the same providers, and run any API-tier comparison on current published rates — Opus 4.7 is now a legacy model, with Anthropic's current lineup being Fable 5.1, Opus 5, Sonnet 5 and Haiku 4.5, so re-check pricing before budgeting. The cheapest, most reversible test you can run.
• Verify your Google Workspace contract. Many FQHCs are already on Google Workspace for back-office. The Gemini Enterprise tier may already be available with HIPAA BAA — check with your Google Cloud contact before clinical use. If you have it, you may already have AI access most FQHCs are paying separately for. If you don't, the upgrade economics may surprise you.

NACHC or OCHIN as a broker

Individual FQHCs have low bargaining leverage with $850-900B AI labs. NACHC has 1,400+ member health centers. OCHIN has 44,000+ providers across 2,200+ sites.

Either organization could broker an FQHC consortium partnership with one or more of the AI labs that would benefit the entire safety-net sector — analogous to WellSky's 20,000-site partnership with Google Cloud or Abridge's FQHC cohort report.

The negotiation asks should include: (1) FQHC-tier pricing analogous to NACHC Select bundled programs, (2) Spanish-language parity at launch (not staged) for any patient-facing AI, (3) FQHC patient population representation in alignment / training data, (4) a published clinical advisor cohort that includes safety-net providers (not just academic medical centers), and (5) free or deeply discounted pilots for the 6-12 month proof-of-value window each lab needs to demonstrate community-health outcomes.

The opportunity is short-lived. Once each lab has its 50 named enterprise customers across hospital systems and pharma, the FQHC market becomes an afterthought — accessible only via SMB API contracts at AMC-tier volume pricing. The window is now, while each lab is hungry to demonstrate clinical impact at meaningful scale. NACHC's P&I Forum, OCHIN's annual meeting, and CHCF's strategic priorities for 2026-2028 all converge on this.

The good news: NACHC is no longer absent from the conversation. Its May 11, 2026 CHAI co-chair role on Medicaid-eligibility AI guides, combined with the ScaleHealth Accelerator 2026 FQHC AI cohort, shows the association is now actively shaping the governance framework rather than just receiving it.

What remains absent is the frontier-lab enterprise partnership at consortium scale. Someone — NACHC, OCHIN, or a CHCF-backed consortium — still has to broker it.